Abstract
Prostate cancer, the most frequently diagnosed neoplasia in men, represents a therapeutic challenge throughout all disease stages. Initial therapy of metastatic prostate cancer consists of androgen ablation, either by drugs (LHRH agonists) or by surgery (bilateral orchiectomy), and responses can be observed in up to 85% of patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Berthold DR, Pond GR, Soban F, de Wit R, et al. (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26: 242–245.
Reichle A, Vogt T (2008) Systems biology: a therapeutic target for tumor therapy. Cancer Microinviron 1(1): 159–170.
Reichle A, Hildebrandt GC (2009) Principles of Modular Tumor Therapy. Cancer Microenviron 2 Suppl 1: 227–237.
Reichle A (2009) Tumor systems need to be rendered usable for a new action-theoretical abstraction: The starting point for novel therapeutic options. Curr Cancer Ther Rev 5: 232–242.
Hartwell LH, Hopfield JJ, Leibler S, et al. (1999) From molecular to modular cell biology. Nature 402(6761 Suppl): C47–52.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Netherlands
About this chapter
Cite this chapter
Reichle, A. et al. (2010). Systems-Directed Therapy in Metastatic Castration-Resistent Prostate Cancer (CRCP). In: Reichle, A. (eds) From Molecular to Modular Tumor Therapy. The Tumor Microenvironment, vol 3. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-9531-2_19
Download citation
DOI: https://doi.org/10.1007/978-90-481-9531-2_19
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-9530-5
Online ISBN: 978-90-481-9531-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)